Datopotamab deruxtecan (Dato-DXd) has been granted Priority Review from the US FDA for advanced EGFR-mutated non-small cell lung cancer (NSCLC) following prior therapies.
The FDA has approved Datroway® (datopotamab deruxtecan-dlnk) for adult patients with unresectable or metastatic HR-positive, ...
The FDA has approved a novel combination therapy using Lumakras® (sotorasib) and Vectibix® (panitumumab) for adults with KRAS ...
Oncolytics Biotech received approval from Germany\u2019s Paul-Ehrlich-Institute to advance Cohort 5 of the GOBLET study, ...
Ariceum Therapeutics announced that the FDA has cleared its investigational new drug application to commence a Phase I/II ...
The Internet of Medical Things (IoMT) is set to radically change the quality of care and outcomes for millions of patients, ...
Artificial Intelligence (AI) can play a crucial role in drug discovery, but the lack of sufficient data in this area remains ...
Novartis announced that its drug Ribociclib (Kisqali®) combined with endocrine therapy (ET) demonstrates a sustained 28.5% reduction in distant recurrence for high-risk HR+/HER2- early breast cancer ...
The US FDA has approved BRAFTOVI® (encorafenib) with cetuximab and mFOLFOX6 as a first-line therapy for BRAF V600E-mutant metastatic colorectal cancer. The Phase 3 BREAKWATER trial showed ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback